ArticleCureus2024
Effective Pain Management of Postherpetic Neuralgia Using a Combination of Analgesics and Conservative Measures.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Current advances in the epidemiology, risk factors, prevention, management, and long-term outcomes of herpes zoster and post-herpetic neuralgia.Frontiers in microbiology · 2026Pooled it
- Association Between Triglyceride Glucose Index and Postherpetic Neuralgia in Patients with Acute Herpes Zoster: A Retrospective Study.Pain and therapy · 2026Article
- Central Sensitization and Nociplastic Pain: Shared Mechanisms in Fibromyalgia, Osteoarthritis, and Inflammatory Arthritis.Journal of pain research · 2026Review
- Impact of Pulsed Radiotherapy on Pain and Quality of Life in Elderly Postherpetic Neuralgia Patients.Medical science monitor : international medical journal of experimental and clinical research · 2025Article
- Efficacy and Safety of Electroacupuncture for Postherpetic Neuralgia and Biomarker Evaluation: A Study Protocol for a Multicenter, Randomized Trial.Journal of pain research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Postherpetic neuralgia (PHN) is characterized by persistent pain following the resolution of a herpes zoster rash. PHN is often resistant to treatment and can significantly reduce the patient's quality of life. Effective symptom relief is crucial and various treatments, including pharmacotherapy, have been attempted. Given that symptoms can persist for a prolonged period, they can substantially affect the physical and mental well-being of the patients. A 73-year-old man developed herpes zoster while undergoing treatment for a head angiosarcoma. Despite the resolution of the rash, the pain persisted, leading to the diagnosis of PHN. Treatment was initiated with a range of medications, including mecobalamin, pregabalin, and a combination of tramadol and acetaminophen, along with general pain relievers standardized as WHO Step 1 medications, which include acetaminophen and non-steroidal anti-inflammatory drugs (NSAIDs). However, achieving adequate pain control is challenging and results in frequent hospitalizations. Due to the patient's depression and the concurrent use of a selective serotonin reuptake inhibitor, duloxetine hydrochloride could not be prescribed. Instead, opioid therapy with continuous fentanyl citrate infusion was initiated. Eventually, the treatment was switched to oxycodone hydrochloride, which successfully stabilized the patient's symptoms. The use of conservative measures such as hot compresses also contributes to symptom relief. Alleviating pain symptoms using a combination of pharmacotherapeutic and non-pharmacological treatments is extremely important.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.